McCarthy HO - Search Results

1

Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.

Donley C, McClelland K, McKeen HD, Nelson L, Yakkundi A, Jithesh PV, Burrows J, McClements L, Valentine A, Prise KM, McCarthy HO, Robson T. Donley C, et al. Among authors: mccarthy ho. Oncogene. 2014 Jun 26;33(26):3441-50. doi: 10.1038/onc.2013.306. Epub 2013 Aug 5. Oncogene. 2014. PMID: 23912458

2

Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.

McCarthy HO, Yakkundi A, McErlane V, Hughes CM, Keilty G, Murray M, Patterson LH, Hirst DG, McKeown SR, Robson T. McCarthy HO, et al. Cancer Gene Ther. 2003 Jan;10(1):40-8. doi: 10.1038/sj.cgt.7700522. Cancer Gene Ther. 2003. PMID: 12489027

3

Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment.

Worthington J, McCarthy HO, Barrett E, Adams C, Robson T, Hirst DG. Worthington J, et al. Among authors: mccarthy ho. J Gene Med. 2004 Jun;6(6):673-80. doi: 10.1002/jgm.567. J Gene Med. 2004. PMID: 15170738

4

A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.

McErlane V, Yakkundi A, McCarthy HO, Hughes CM, Patterson LH, Hirst DG, Robson T, McKeown SR. McErlane V, et al. Among authors: mccarthy ho. J Gene Med. 2005 Jul;7(7):851-9. doi: 10.1002/jgm.728. J Gene Med. 2005. PMID: 15712360

5

Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.

Yakkundi A, McErlane V, Murray M, McCarthy HO, Ward C, Hughes CM, Patterson LH, Hirst DG, McKeown SR, Robson T. Yakkundi A, et al. Among authors: mccarthy ho. Cancer Gene Ther. 2006 Jun;13(6):598-605. doi: 10.1038/sj.cgt.7700933. Cancer Gene Ther. 2006. PMID: 16410820

6

p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.

McCarthy HO, Worthington J, Barrett E, Cosimo E, Boyd M, Mairs RJ, Ward C, McKeown SR, Hirst DG, Robson T. McCarthy HO, et al. Gene Ther. 2007 Feb;14(3):246-55. doi: 10.1038/sj.gt.3302871. Epub 2006 Sep 28. Gene Ther. 2007. PMID: 17006546

7

Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.

McCarthy HO, Coulter JA, Worthington J, Robson T, Hirst DG. McCarthy HO, et al. J Gene Med. 2007 Jun;9(6):511-20. doi: 10.1002/jgm.1045. J Gene Med. 2007. PMID: 17471586

8

The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.

Coulter JA, McCarthy HO, Worthington J, Robson T, Scott S, Hirst DG. Coulter JA, et al. Among authors: mccarthy ho. Gene Ther. 2008 Apr;15(7):495-503. doi: 10.1038/gt.2008.7. Epub 2008 Feb 7. Gene Ther. 2008. PMID: 18256696

9

Nitric oxide--a novel therapeutic for cancer.

Coulter JA, McCarthy HO, Xiang J, Roedl W, Wagner E, Robson T, Hirst DG. Coulter JA, et al. Among authors: mccarthy ho. Nitric Oxide. 2008 Sep;19(2):192-8. doi: 10.1016/j.niox.2008.04.023. Epub 2008 Apr 29. Nitric Oxide. 2008. PMID: 18485922 Review.

10

Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype.

Butterworth KT, McCarthy HO, Devlin A, Ming L, Robson T, McKeown SR, Worthington J. Butterworth KT, et al. Among authors: mccarthy ho. Int J Cancer. 2008 Aug 15;123(4):760-8. doi: 10.1002/ijc.23418. Int J Cancer. 2008. PMID: 18512241

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

184 results

Search Page

Filters